

981, 678

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 July 2003 (31.07.2003)

PCT

(10) International Publication Number  
**WO 03/061656 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/44**,  
31/195

(21) International Application Number: PCT/US03/00794

(22) International Filing Date: 10 January 2003 (10.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/349,773 16 January 2002 (16.01.2002) US

(71) Applicant (for all designated States except US): **ENDO  
PHARMACEUTICALS INC.** [US/US]; 100 Painters  
Drive, Chadds Ford, PA 19317 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GALER, Bradley,**  
S. [US/US]; 1740 Lenape Road, West Chester, PA 19382  
(US). **SCHLAGHECK, Thomas, G.** [US/US]; 14 Warren  
Street, Rumson, NJ 07760 (US).

(74) Agents: **BREW, Michael, R.** et al.; Dilworth & Barrese,  
LLP, 333 Earle Ovington Blvd., Uniondale, NY 11553  
(US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN,  
YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,  
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM**

(57) Abstract: Disorders of the ventral nervous system (CNS) are treated by the administration of a GABA analog such as gabapentin or pregabalin, an NMDA receptor antagonist such as dextromethorphan or d-methadone and, optionally, another pharmacologically active substance, e.g., one which is effective for the treatment of a CNS disorder.

WO 03/061656 A1